Publication
Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerMalignant Neoplasmcivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneBRAFcivic_curation1.00
- geneDUSP6civic_curation1.00
- geneKRAScivic_curation1.00
- variantBRAF Mutationcivic_curation1.00
- variantDUSP6 EXPRESSIONcivic_curation1.00
- variantKRAS Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22169769
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF Mutation1 | ||||||||
| Trametinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID936In this screen of 218 solid cancer cell lines, BRAF mutations were predictive of response to the MEK inhibitor GSK1120212. 26 of these cell lines had the BRAF V600E mutation, one cell line had a G469A… (full text at CIViC) PMID 22169769 · Jing et al., 2012 · Open in CIViC | civic |
| DUSP6 EXPRESSION1 | ||||||||
| Trametinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID934Expression of DUSP6 was associated with sensitivity to MEK inhibitor GSK1120212 (Sensitivity: 79%; specificity: 82%: P = 0.0027) in 218 solid cancer cell lines. PMID 22169769 · Jing et al., 2012 · Open in CIViC | civic |
| KRAS Mutation1 | ||||||||
| Trametinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID935In this screen of 218 solid cancer cell lines, KRAS and BRAF mutations were predictive of response to MEK inhibitor GSK1120212. 40 cell lines harbored a KRAS mutation. In RAF/RAS mutant colon cancer c… (full text at CIViC) PMID 22169769 · Jing et al., 2012 · Open in CIViC | civic |